In a report released today, Florent Cespedes from Bernstein maintained a Hold rating on Novo Nordisk (0QIU – Research Report), with a price ...

Minnesota Attorney General Keith Ellison and pharmaceutical company Novo Nordisk reached a settlement to cap insulin costs at ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a ...

Novo Nordisk’s haemophilia A therapy Mim8 stopped bleeding completely in 74.3% of children in a Phase III trial. The ...

The settlement filed in Newark, N.J. federal court comes after similar settlements with Eli Lilly and Sanofi last year. It ...

Evaluate’s latest analysis forecasts an $82 billion increase in major product revenues in 2025 – the largest annual growth ...

The remarkable efficacy of new diabetes and weight loss medicines like Ozempic and Mounjaro have been one of the biggest health stories of recent years. Despite rising rates of diabetes and obesity, ...

Given Sobi's cash flow generation from its hemophilia business and mature product Synagis, the firm ended 2024 with a net debt/EBITDA ratio of 1.6 times. We expect the firm can support this level of ...

Amazon Music and WPP unveiled Louder Than Cancer, an effort uniting top global artists to harness the power of music in recognition of World Cancer Day with creative leadership from WPP’s Grey Health, ...

Life Sciences Ontario (LSO) proudly announces the recipients of the 2025 LSO Awards, celebrating excellence and innovation in life sciences. Now in its 22nd year, the LSO Awards continues its ...

Novo Nordisk reported strong sales growth for its Wegovy and Ozempic drugs, while its 2025 guidance topped expectations. Shares in Novo, one of Europe's largest listed companies, rallied in the U.S.